Malin Corporation PLC Immunocore Files for Potential IPO on Nasdaq (9355L)
18 January 2021 - 6:00PM
UK Regulatory
TIDM0Y71
RNS Number : 9355L
Malin Corporation PLC
18 January 2021
Malin Corporation plc
Immunocore Files for Potential Initial Public Offering on the
Nasdaq Global Market
Dublin-Ireland, 18 January 2021 : Malin Corporation plc.
(Euronext Growth Dublin:MLC) (Malin), a company investing in highly
innovative life sciences companies, today notes that its investee
company, Immunocore, has filed a registration statement on Form F-1
(Registration Statement) with the US Securities and Exchange
Commission (SEC) relating to a proposed initial public offering in
the United States of American Depositary Shares (ADSs) of
Immunocore, each representing one ordinary share of Immunocore. All
ADSs to be sold in the proposed initial public offering will be
offered by Immunocore. The number of ADSs to be sold and the
pricing terms for the proposed IPO have not yet been
determined.
Immunocore has applied to list its ADSs on the Nasdaq Global
Market under the symbol "IMCR". The number of ADSs to be offered
and the price terms for the proposed offering have not yet been
determined. The initial public offering is subject to market
conditions, and there can be no assurance as to whether, or when,
the offering may be completed or as to the actual size or terms of
the offering.
The Registration Statement relating to the ADSs has been filed
with the SEC but has not yet become effective. The ADSs may not be
sold, nor may offers to buy be accepted, prior to the time the
Registration Statement becomes effective. The offering will be made
only by means of a prospectus. A copy of the preliminary
prospectus, when available, may be obtained from the SEC's EDGAR
database and contains further information relating to
Immunocore.
This press release does not constitute an offer to sell or the
solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such jurisdiction.
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in
highly innovative life sciences companies. Its purpose is to create
shareholder value through the application of long-term capital and
operational and strategic expertise to a diverse range of global
healthcare businesses. Malin has a focus on innovative businesses
underpinned by exceptional science and works with its investee
companies, providing strategic and financial support to enable them
to reach their value potential. Malin is headquartered and
domiciled in Ireland and listed on the Euronext Growth Dublin. For
more information visit www.malinplc.com
About Immunocore
Immunocore is a late-stage biotechnology company pioneering the
development of a novel class of TCR bispecific immunotherapies
called ImmTAX - Immune mobilising monoclonal TCRs Against X disease
- designed to treat a broad range of diseases, including cancer,
infectious and autoimmune.
For further information please contact:
Malin
Jessica Bergin, Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Davy Corporate Finance (Euronext Growth Adviser & Joint
Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
Liberum (Joint Broker)
Bidhi Bhoma / Euan Brown
Tel: +44 (0) 20 3100 2000
Powerscourt (Irish Media enquiries)
Jack Hickey
Tel: +353 83 4488339
malin@powerscourt-group.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUAWGUPGGCM
(END) Dow Jones Newswires
January 18, 2021 02:00 ET (07:00 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Apr 2024 to May 2024
Malin (LSE:0Y71)
Historical Stock Chart
From May 2023 to May 2024